USPTO serial 97442381
T-DETECT
Reviewed by CopyMark Law Group
Status 606
- Filing date
- Status date
- Registration date
- —
- Examiner
- OSBORNE, AUDRIANA R
- Law office
- INTENT TO USE SECTION
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with T-DETECT?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Hoang-chi Truong
Hoang-chi Truong Patent Law Works LLP4516 South 700 East, Suite 290SALT LAKE CITY, UT 84107United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Diagnostic kits comprised of medical diagnostic reagents and assays for testing of bodily fluids for use in disease detection, namely, to detect cancer, autoimmune disease and infection; Medical assay kits comprised of diagnostic reagents and assays for medical use, namely, to detect cancer, autoimmune disease and infection; Diagnostic kits comprised of medical immunosequencing-based diagnostic reagents and assays for testing of bodily fluids for use in disease detection, namely, to detect cancer, autoimmune disease and infection; Medical immunosequencing assay kits comprised of diagnostic reagents and assays for medical use , namely, to detect cancer, autoimmune disease and infection; Medical immunosequencing-based assay kits comprised of medical grade reagents and sample plates for detecting cancer, autoimmune disease and infection | ACTIVE | — |
| 042 | Providing information about medical research in the field medical diagnostic assays and diagnostic and prognostic testing for medical research purposes of residual disease, and the analysis, evaluation, and reporting of those test results to help healthcare professionals for research purposes; development of new technology for others in the field of biotechnology; DNA analysis services for scientific research purposes; genetic testing for scientific research purposes; genome amplification; genotyping services for research or analysis purposes; laboratory research in the field of immune sequencing; medical and scientific research in the field of cancer treatment and diagnosis; medical and scientific research in the field of immune sequencing; providing laboratory research services in the field of gene expression, namely, cancer biology; providing medical and scientific research information in the field of clinical trials; providing medical and scientific research information in the fields of pharmaceuticals and genetics; research and development in the pharmaceutical and biotechnology fields; research, development, engineering and testing services in the fields of immunopharmaceuticals and vaccines; scientific research in the field of genetics and genetic engineering; DNA screening for scientific research purposes; medical research; consulting services in the fields of biotechnology, pharmaceutical research and development and genetic science; consulting services in the fields of laboratory testing, diagnostics, and pharmacogenetics; custom design and development of chemical reagents and biochemical assays; development of new technology for others in the field of immunotherapy; laboratory research in the field of immunotherapy, oncology, hematology, auto-immune disorders, and infectious diseases; medical and scientific research in the field of immunotherapy; medical laboratory services; medical laboratory immunosequencing-based services for analysis of biological samples | ACTIVE | — |
| 044 | Providing medical diagnostic assays and diagnostic and prognostic testing for treatment purposes of residual disease, and the analysis, evaluation, and reporting of those test results to help healthcare professionals determine a patient's clinical diagnosis, the effectiveness of patient treatments, and to revise future treatments accordingly; medical services; consulting services in the field of medical diagnostic and prognostic testing; medical diagnostic and prognostic testing services; providing medical immunosequencing-based diagnostic and prognostic testing for cancer, autoimmune disease and infection; consulting services in the field of medical immunosequencing-based testing; medical analysis services for diagnostic and treatment purposes provided by medical laboratories; Medical analysis services relating to the diagnosis and treatment of persons | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Adaptive Biotechnologies Corp.
- Other trademarks owned by Adaptive Biotechnologies Corp.
- Other trademarks in Class 005
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named T-DETECT
- Prosecution event MAB6 explained
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Oct 28, 2024 | MAB6 | ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Oct 28, 2024 | ABN6 | ABANDONMENT - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Mar 23, 2024 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Mar 22, 2024 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Mar 22, 2024 | EXT1 | SOU EXTENSION 1 FILED | — |
| Mar 22, 2024 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Sep 26, 2023 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Aug 1, 2023 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Aug 1, 2023 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jul 12, 2023 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Jun 27, 2023 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jun 23, 2023 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jun 22, 2023 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jun 22, 2023 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Mar 22, 2023 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 22, 2023 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 22, 2023 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 20, 2023 | DOCK | ASSIGNED TO EXAMINER | — |
| Jun 14, 2022 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jun 7, 2022 | NWAP | NEW APPLICATION ENTERED | — |